NEW YORK, Jan. 17, 2017 /PRNewswire/ -- Attorney Advertising --
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alcobra Ltd. ("Alcobra"
or the "Company") (NASDAQ: ADHD). Such investors are encouraged to obtain additional information and assist the investigation by
visiting the firm's site: www.bgandg.com/adhd.
The investigation concerns whether Alcobra and certain of its officers and/or directors have violated Sections 10(b) and 20(a)
of the Securities Exchange Act of 1934.
On January 17, 2017, pre-market, Alcobra revealed that its attention deficit hyperactivity
disorder drug, Metadoxine Extended Release, failed to meet its primary endpoint in its Phase 3 trial. Following this news,
Alcobra stock dropped $0.97 per share, or 50.82%, to close at $0.94
January 17, 2017.
If you are aware of any facts relating to this investigation, or purchased Alcobra shares, you can assist this investigation
by visiting the firm's site: www.bgandg.com/adhd. You can
also contact Peretz Bronstein or his Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive
pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as
well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-alcobra-ltd-adhd-300392288.html
SOURCE Bronstein, Gewirtz & Grossman, LLC